Genetic Testing Clinical Trial
— AGILITYOfficial title:
Access to Genetic Information Leveraging Innovative Technology
AGILITY is a type 1 hybrid trial that will test the effectiveness of a chatbot to provide pre-test information about genetic screening for tier 1 conditions. A randomized control trial of 2400 adult participants from diverse primary care clinics at the University of Florida Gainesville to receive virtual information about tier 1 condition genetic testing from a chatbot or traditional genetic counseling. The assessment of the outcome of the trial is to determine whether the chatbot is inferior to genetic counseling. Non-inferiority will be determined based on informed choice to undergo testing (or not). Implementation outcomes of acceptability, feasibility, and appropriateness will be evaluated to inform future potential through interviews with patients, primary care providers and GCs.
Status | Not yet recruiting |
Enrollment | 2400 |
Est. completion date | September 2025 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years or older - Male or Female - University of Florida Gainesville primary care patients - Negative family history for hereditary breast and ovarian cancer, and Lynch syndrome and familial hypercholesterolemia Exclusion Criteria: - Positive family history of hereditary breast and ovarian cancer, and Lynch syndrome, and familial hypercholesterolemia |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
RTI International | University of Florida |
Ames AG, Jaques A, Ukoumunne OC, Archibald AD, Duncan RE, Emery J, Metcalfe SA. Development of a fragile X syndrome (FXS) knowledge scale: towards a modified multidimensional measure of informed choice for FXS population carrier screening. Health Expect. 2015 Feb;18(1):69-80. doi: 10.1111/hex.12009. Epub 2012 Oct 15. — View Citation
Dormandy E, Hooper R, Michie S, Marteau TM. Informed choice to undergo prenatal screening: a comparison of two hospitals conducting testing either as part of a routine visit or requiring a separate visit. J Med Screen. 2002;9(3):109-14. — View Citation
Jaques AM, Sheffield LJ, Halliday JL. Informed choice in women attending private clinics to undergo first-trimester screening for Down syndrome. Prenat Diagn. 2005 Aug;25(8):656-64. — View Citation
Lewis MA, Paquin RS, Roche MI, Furberg RD, Rini C, Berg JS, Powell CM, Bailey DB Jr. Supporting Parental Decisions About Genomic Sequencing for Newborn Screening: The NC NEXUS Decision Aid. Pediatrics. 2016 Jan;137 Suppl 1:S16-23. doi: 10.1542/peds.2015-3731E. — View Citation
Li M, Bennette CS, Amendola LM, Ragan Hart M, Heagerty P, Comstock B, Tarczy-Hornoch P, Fullerton SM, Regier DA, Burke W, Trinidad SB, Jarvik GP, Veenstra DL, Patrick DL. The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation. J Genet Couns. 2019 Apr;28(2):477-490. doi: 10.1007/s10897-018-0286-9. Epub 2018 Dec 14. — View Citation
O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995 Jan-Mar;15(1):25-30. — View Citation
Turbitt E, Chrysostomou PP, Peay HL, Heidlebaugh AR, Nelson LM, Biesecker BB. A randomized controlled study of a consent intervention for participating in an NIH genome sequencing study. Eur J Hum Genet. 2018 May;26(5):622-630. doi: 10.1038/s41431-018-0105-7. Epub 2018 Feb 16. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Informed Choice | The number of participants that made an informed choice (Multi-dimensional Model of Informed Choice) following a chatbot intervention compared to the number of participants that made an informed choice following genetic counseling. Informed choice is measured using a composite tool that includes understanding of relevant knowledge (1-8 items-higher scores indicate greater knowledge), attitudes toward testing (1-5 items-higher scores represent more positive attitudes), and whether the test decision is congruent with personal values (positive or negative about testing in relation to whether testing was accepted or declined). | Immediately after arm completion | |
Secondary | Test-related Affect | Compare Test-related affect scale response assessed by the Feelings About Genomic Testing Results Scale (Response ranges 0-12 on the negative emotions subscale, 0-16 on the positive feelings subscale, 0-12 on the uncertainty subscale, and 0-8 on the privacy concerns subscale, all with a higher score indicating greater functional impairment.) between usual care and the intervention group at 3 months. | 3 months | |
Secondary | Test-related Affect | ompare Test-related affect scale response assessed by the Feelings About Genomic Testing Results Scale (Response ranges 0-12 on the negative emotions subscale, 0-16 on the positive feelings subscale, 0-12 on the uncertainty subscale, and 0-8 on the privacy concerns subscale, all with a higher score indicating greater functional impairment.) between usual care and the intervention group at 6 months. | 6 months | |
Secondary | Decisional Conflict | Compare Decisional conflict assessed by the Ottawa Decisional Conflict Scale (Response range 1-10 higher scores denote greater decisional conflict) between usual care and the intervention group at 3 months. | 3 months | |
Secondary | Decisional Conflict | Compare Decisional conflict assessed by the Ottawa Decisional Conflict Scale (Response range 1-10 higher scores denote greater decisional conflict) between usual care and the intervention group at 6 months. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03988504 -
Impact of Predictive Genetic Testing
|
||
Recruiting |
NCT02691689 -
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions
|
N/A | |
Completed |
NCT04704193 -
Development and Implementation of Electronic Decision Aids for Genetic Testing in Inherited Cancer Syndromes
|
N/A | |
Completed |
NCT05545254 -
Health-promoting Lifestyle in a Genetic Counseling Clinic
|
||
Recruiting |
NCT05348564 -
Comparing Direct vs Indirect Methods for Cascade Screening
|
N/A | |
Recruiting |
NCT05360095 -
Comparing Game Facilitated Interactivity to Genetic Counseling for Prenatal Screening Education
|
N/A | |
Active, not recruiting |
NCT03869515 -
Genetic Causes and Clinical Features of Childhood Interstitial Lung Diseases in China
|
||
Recruiting |
NCT04856696 -
Clinical Application of Non-invasive PGT-A
|
N/A | |
Recruiting |
NCT04481061 -
Engaging Adolescents in Decisions About Return of Genomic Research Results
|
N/A | |
Recruiting |
NCT04656028 -
Genetic Testing and Motivational Counseling for FH
|
N/A | |
Completed |
NCT02742116 -
Evaluation of the Implementation of Expanded Carrier Screening Before Pregnancy in Hong Kong
|
N/A | |
Recruiting |
NCT03396341 -
Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations
|
||
Active, not recruiting |
NCT04245176 -
Genetic Testing for All Breast Cancer Patients (GET FACTS)
|
N/A | |
Active, not recruiting |
NCT02665195 -
Prospective Registry of Multiplex Testing (PROMPT)
|
||
Recruiting |
NCT06073626 -
Personalized Oncology Promoting Equity for Black Lives
|
N/A | |
Recruiting |
NCT05225428 -
Video Education With Result Dependent dIsclosure
|
N/A | |
Active, not recruiting |
NCT05265624 -
The Moran AMD Genetic Testing Assessment Study
|
Phase 2 | |
Withdrawn |
NCT01663584 -
Multi-disease Carrier Screening Test Validation
|
N/A | |
Recruiting |
NCT05055700 -
Impact of a Mobile App on Pregnant Women's Prenatal Genetic Testing Decision-making
|
N/A |